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ABSTRACT 
Mycobacterium tuberculosis is the bacteria that cause tuberculosis (TB), an infection that usually affects the lungs and can be fatal without proper 
treatment. Combating through available drugs became a difficult task due to drug resistance and lack of appropriate common targets against 
genetically diverse strains. Since to improve efficacy, the effective targets should be identified and critically assessed. In the study, we aim to 
predict the potential novel targets against M. tuberculosis strains by employing in silico approach. The complete proteomic datasets of 23 M. 
tuberculosis strains was comparatively processed by executing R-scripts and eventually predicted 3906 'conserved gene products'. Further, we 
performed subtractive proteomic approach in search of promising crucial targets. Consequently, eight enzymes and two membrane proteins 
were prioritized as new therapeutic and vaccine targets respectively which found to have more interactors in network with high-confidence 
score, druggability and antigenicity. Therefore, outcomes of the study emphasize the importance of new targets may counteract with false-
positive/negatives and facilitate appropriate potential targets for a new insight of reliable therapeutic development. 
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1. INTRODUCTION 
Tuberculosis (TB) is one of the major infectious diseases 
affecting human beings caused by Mycobacterium 
tuberculosis. Tuberculosis is either latent or active, latent TB 
means the TB bacteria is in the body, but the body's defenses 
(immune system) are keeping it static from turning into 
active TB 1. Latent TB also called inactive TB or TB infection 
isn't contagious. It can turn into active TB, so treatment is 
important for the person with latent TB to prevent its 
conversion to active form. The symptoms of TB depend on 
the area of which the body has been infected; primary 
infection of tuberculosis might affect the lungs, 
pulmonary tuberculosis (PTB) complications include 
hemoptysis, pneumothorax, bronchiectasis, malignancy 
and chronic pulmonary aspergillosis 2. Symptoms of TB 
include fatigue, weight loss, and lack of appetite, chills, fever 
and night sweats. An extra pulmonary (EP) infection can 
affect any part of the body, the infection spreads through 
hematogenous route i.e., mainly through blood to the 
other sites of the body like urinary tract, genital tract, 
bones and joints etc 3. Genital TB generally occurs as 
secondary to pulmonary (commonest) or extrapulmonary 
TB like gastrointestinal tract, kidneys, skeletal system, 
meninges and miliary TB through hematogenous and 
lymphatic route. Over 95 % of new TB cases and deaths 
occur in developing countries with India accounting for 40 % 
of the world’s TB burden 4. Co-infection with human 
immunodeficiency virus (HIV) patients with more liberal 
immigration from high risk to low-risk areas due to 
globalization has been responsible for increased incidence 
all over the world 5. 
Globally, 10.4 million new cases of active TB were estimated 
among which 1.2 million HIV positive people are included, of 
the 3.5 million were women and 1.0 million were children. 
About 1,70,000 children have died of TB (excluding children 
with HIV) 6. World Health Organization (WHO) recommends 
the patient should have six months of TB drug treatment 
(WHO 2015). This consists of a two month “intensive” 
treatment phase followed by a four-month “continuation” 
phase 7. Improper treatment or interruption to medication 
uptake makes M. tb resistance to drugs 8. Adults with drug-
resistant TB should always receive an effective second-line 
injectable agent as part of their regimen. The emergence of 
antibiotic resistance M. tuberculosis around the world owes 
as a genetically more diverse form. The resistance 
mechanisms during evolution described to date are due to 
Nalamolu et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):67-71 
ISSN: 2250-1177                                                                                  [68]                                                                                 CODEN (USA): JDDTAO 
point mutations on the bacterial chromosome considerably 
results in phenotypic variations in M. tuberculosis strains. 
The prevalence of antibiotic resistance appears to be partly 
determined by geographical factors. Increase in multi-drug 
resistance (MDR) and extensively drug-resistance (XDR) 
were also reported in tuberculosis cases 9. 
Therefore, the WHO (2016) changed their recommendations 
on the use of drugs for the treatment of drug-resistant TB. 
However, adverse effects need to be carefully monitored 
while using injectable effective agents. For instance, hearing 
loss and nephrotoxicity are the most frequent severe side 
effects 10. 
Despite, Bacille Calmette-et-Guerin (BCG) vaccine provides 
minimal immunity or protection against TB; it is causing side 
effects like swollen lymph nodes, small red areas at the site 
of injection, fever, blood in urine, frequent or painful 
urination, upset stomach and vomiting 11. To overcome the 
adverse, side effects and non-efficacious drugs and vaccines 
in treating and preventing TB caused by MDR and XDR 
strains, there is an emergent need to discover novel, 
potential drug targets and vaccine candidates for effective 
TB therapeutics design. Therefore, in the current study, we 
aim to predict novel potent drug targets and vaccine 
candidates against MDR and XDR M. tuberculosis strain 
through in silico approaches. 
The experimental approaches are tedious and laborious 
obtain very few results hence computational approaches 
were used to identify the putative drug targets. Comparative 
proteomic approach, subtractive proteomic approach, 
metabolic pathway analysis, non-homologous gut flora 
analysis, domain search analysis, and protein network 
analysis are extensively used for the prediction of potential 
drug targets of the pathogen causing TB. In this scenario, 
potential targets must be essential for the growth and 
survival of the pathogen. Further designing of inhibitors 
should hinder the function exclusively the pathogen and 
should avoid the undesirable cross-reactivity with the 
human proteins. The availability of complete proteome 
sequences of the selected pathogen in combination with 
Bioinformatics tools and databases is of great importance in 
reducing the problem of searching for potential drug 
targets/vaccine candidates in a large pool of proteomes. 
Therefore, in the current study, we intended to explore 
potential novel therapeutic and vaccine candidates from 
numerous genetically diverse M. tuberculosis strains 
inhabitants around the globe for designing new reliable 
broad-spectrum inhibitors. 
2. MATERIALS AND METHODS 
2.1. Comparative Proteomic Analysis and Dataset 
Preparation: 
We used proteomes of 23 virulent M. tb strains in the current 
study, among them M. tb_H37Rv strain was considered as a 
reference due to its predominant role in TB 12. Complete 
proteomes were retrieved from the National Center for 
Biotechnology Information (NCBI), an imperative resource 
for enormous biological information 13. In comparative 
proteomic approach, data processing was done using in-
house bash and R scripts in Linux environment for 
downstream dataset preparation and quantification in order 
to get conserved (common) proteins 14. 
2.2. Subtractive Proteomic Approach: 
Common protein sequences were subjected for non-human 
homology 15 by aligning each protein against human 
proteome for unidentical protein sequences or protein 
sequences with less than 30 % identity. 
2.3. Gene Essentiality and Non-human Homology 
Analysis: 
The derived dataset of conserved proteins was carried to 
target screening using different channels that optimizes a 
large number of conserved proteins to few putative targets. 
In order to screen essential gene products from the dataset, 
essential gene analysis was performed using the Database of 
Essential Genes (DEG) accessed at 
http://tubic.tju.edu.cn/deg/ 15. Essential proteins were 
further assigned to non-homology analysis against human 
proteome 16. The query sequence that did not match any hit 
better than the threshold (bit score of >100) were 
considered as ‘M. tuberculosis-specific’ protein. Protein 
alignments with an expectation value of (E- value) < 10−10 
were considered as more significant hits. Such proteins were 
regarded as essential, based on the assumption that similar 
proteins that are essential in one organism are likely to be 
essential in another 17.  
2.4. Analysis of Non-homology against Host: 
The aim of the non-homology analysis is to identify pathogen 
specific-proteins that are non-homologous to the host. The 
significance of this step is to minimize undesirable cross-
reactivity of the drug thereby preventing its binding to active 
sites of the host’s homologous proteins. Essential proteins 
were further assigned to non-human homologous analysis, 
protein alignments E-value >10-3 was considered as non-
human homologous proteins as described in a previous 
study 18. The aim of non-human homology analysis against 
host is to identify pathogen specific-proteins. The 
significance of this step is to minimize undesirable cross-
reactivity of the inhibitors with host proteins. The essential 
protein dataset was searched for non‐host homology 
analysis to identify common proteins of M. tb strains. 
2.5.  Host-pathogen Metabolic Pathway Analysis: 
KEGG (Kyoto Encyclopaedia of Genes and Genome) accessed 
at http://www.genome.jp/pathways.html 19 is a pathway 
database used as a source of metabolic pathway information. 
Pathways which do not appear in the host but present in the 
pathogen according to KEGG database have been identified 
as pathways unique to M. tuberculosis. The corresponding 
protein sequences of enzymes involved in unique pathways 
were identified 20. The pathways of drug targets were 
checked and the drug targets having alternative pathways 
were not considered because blocking of these drug targets 
would be ineffective as the product is synthesized by the 
alternative way. 
2.6. Non-homology Analysis against Human Gut-flora 
and Domains: 
All delineated proteins were sought out for similarity search 
with the proteome of human gut-flora taken from literature 
reports 21 to evade adverse reactions of chemical inhibitors 
on host microbiome. Further, the shortlisted enzymes were 
searched against homologous human domains in Pfam and 
SMART (Simple Modular Architecture Research Tool) 
databases to eliminate host’s domain level similar protein 
sequences of MTB, which comprise a large collection of 
protein families. Finally, the selected enzymes that are un-
identical to human proteins/domains were considered as 
putative targets for validation. 
2.7. Protein Interaction Network Analysis: 
Analysis of protein-protein networks of the derived target 
proteins was performed through STRING v10.0, a database 
providing critical assessment and integration of protein-
protein interactions, including direct (physical) as well as 
indirect (functional) associations 22. The preferred high 
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confidence interactions with score ≥ 0.700 and not more 
than 50 interactors were set to acquire significant target 
proteins possess with higher interactomes in the networks 
as well as to avoid false positives and false negatives. The 
identified targets that are specific and important in various 
metabolic networks of the pathogen were considered as 
putative drug targets. 
The confidence score of a target = 
Number of interactants of target enzyme by used methods 
Total number of methods used 
2.8. Subcellular Localization Prediction: 
Cellular locations of the key target proteins were identified 
using PSORTb v3.0.2 [24].  Further validated with Subcellular 
localization of the identified drug targets could be used to 
obtain information about their potential functions. 
Subcellular location of the potential target differentiates 
cytoplasmic, periplasmic or inner membrane proteins that 
are metabolically important drug targets and outer 
membrane or extracellular proteins as vaccine candidates. 
Broad spectrum candidates were classified as either drug 
targets or vaccine candidates based on their subcellular 
localization using PSORTb and further validated with CELLO 
v2.5. The tools that employ four types of sequence coding 
schemes such as ABC transporter proteins and sequence 
composition based on physicochemical properties of amino 
acids. Moreover, the obtained surface exposed proteins were 
tested for their antigenicity using VaxiJen server for 
prediction of protective antigens, tumor antigens where 
antigenic proteins showing score more than the threshold 
(0.4) were predicted as good antigens and affirmed as 
subunit vaccines candidates. 
3. RESULTS AND DISCUSSION 
3.1. Comparative and subtractive proteomic analysis:  
As shown in table (1), The common proteins from 
chromosomal and plasmid DNAs were preferred for target 
screening as being conserved among several strains could be 
useful in implementing a common inhibitor. Execution of R-
scripts and codes could facilitate the proteome-wide 
comparison of total 92,325 proteins of 23 M. tuberculosis 
strains obtained 3906 M. tb specific common proteins. The 
dataset derived from the comparative and subtractive 
proteomic approach has been illustrated in Figure (1); 
composed of conserved proteins with 30–100% identity. 
  
 
Figure 1: Comparative and subtractive drug target identification approach 
3.2. Gene essentiality and non-homology analysis: 
As shown in table (1), Essential genes are indispensable to 
maintain cellular life, as they are vital for replication, 
survival, and viability of the pathogen. Of the common 
proteins, about 1,458 essential proteins were derived by dint 
of essentiality analysis. Subsequently, a non-human 
homologous search of essential proteins had ensued 703 
proteins were absent in host (human) and are of great 
concern in view of designing drugs absolutely specific for the 
pathogen. 
 
Table 1: Identification of common Drug targets and vaccine candidate of M.tb strains 
No. Analyzed criteria Outcome from the target screening 
1. Proteins in 23 MTB strains 92,325 
2. Common proteins among 23 MTB strains 3906 
3. Predicted essential common genes products 1458 
4. Predicted non-human homologs 703 
5. Pathogen specific unique proteins and enzymes of pathway analysis 521 
6. Unique proteins without alternative pathway analysis 282 
7. Non-homologous to gut microbiota 42 
8. Non- homologous to human domains 12 
9. Proteins with high interaction networks 8 
10. Surface exposed membrane proteins after subcellular location 2 
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3.3. Metabolic functional association and potential drug 
targets: 
As shown in table (1), Comparative metabolic pathway 
analysis of non-homologous proteins had unveiled 521 
unique proteins comprises 239 enzymes and 282 non-
enzymes including membrane proteins, which are absent in 
H. sapiens (distinct pathways). In the present study, 
metabolic pathways namely porphyrin and chlorophyll, 
Glycerophospholipid metabolism, arginine and proline 
metabolism, glyoxylate and dicarboxylate carbon 
metabolism, phenylalanine, tyrosine and tryptophan 
metabolism, carotenoid biosynthesis, streptomycin 
biosynthesis polyketide sugar unit biosynthesis, glutathione 
metabolism and carbon metabolism contributed to the final 
drug targets list derived from the utmost analyses . 
As shown in table (2), Pathways which are not present in 
the Homo sapiens but present in the Mycobacterium are 
designated as unique pathways.  Design and targeting 
inhibitors against these non-homologous sequences could be 
the better approach for the generation of new drugs. Thus 
total 8 unique metabolic pathways have been taken in M. 
tuberculosis.
 
Table 2: Proposed common drug targets for M. tb 
No. Protein Name Pathway Essential 
enzymes 
Biological Process Molecular Function 
1. Protoheme IX farnesyl 
transferase (2.5.1.36) 
Porphyrin and chlorophyll  Heme Biosynthesis Transferase 
2. Phosphatidyl serine 
decarboxylase proenzyme 
(4.1.1.36) 
Glycerophospholipid 
metabolism 
Lipid biosynthesis, lipid 
metabolism, Phospholipid 
biosynthesis, Phospholipid 
metabolism 
Decarboxylase, lyase 
3. 1 pyrroline- 5-carboxylate 
dehydrogenase (1.2.1.88) 
Arginine and proline 
metabolism 
Proline catabolic process to 
glutamate 
Nucleotide binding 
4. Putative isocitrate lyase 
metabolism 
(4.1.3.1) 
Glyoxylate and 
dicarboxylate carbon 
Isocitrate metabolic process Isocitrate lyase 
activity 
5. Phospho-2- dehydro-3-
deoxyheptonate aldolase 
(2.5.1.54) 
Phenylalanine, tyrosine and 
tryptophan 
Chorismate biosynthetic 
process 
3-deoxy-7-
phosphoheptulonate 
synthase activity 
6. Phytoene synthase          
(2.5.1.99)                                         
Carotenoid biosynthesis carotenoid biosynthetic 
process 
Farnesyl-diphosphate 
farnesyl transferase 
activity 
7. dTDP-glucose 4, 6-dehydratase 
(4.2.1.46) 
Streptomycin biosynthesis Polyketide sugar subunit 
biosynthesis 
Coenzyme binding 
8. Isocitrate dehydrogenase 
(1.1.1.42)            
Glutathione metabolism, 
carbon metabolism 
Isocitrate metabolic process Isocitrate 
dehydrogenase 
activity 
 
3.4. Gut microbiota analysis: 
As shown in table (1), Gut microorganisms benefit the host 
in many ways such as cleaning the energy from the 
fermentation of undigested carbohydrates, synthesizing 
vitamins, subsequent absorption of short-chain fatty acids, 
degrading xenobiotics etc. The human microflora helps in 
numerous ways which provide resistance to colonization by 
pathogenic bacteria and indigenous opportunists by 
influencing the host immune system. Drug designed should 
neither harm the host enzymes nor hinder the function of 
enzymes of the gut flora which leads to side effects. 
Disruption of gut microbiota results in the development of 
many numerous pathologies in human health. As a result of 
the human gut-flora analysis, about 42 enzymes out of 239. 
So, if design a drug for these non-homologous proteins that 
do not hinder the functioning of the human gut microbiota 
enzymes. 
3.5. Domain search: 
The domain similarity search between M. tuberculosis and 
host ensured the elimination of the protein domains which 
are homologous to host. Domain analysis using the Pfam and 
SMART databases resulted out 8 enzymes. 
3.6. Protein network Analysis: 
The selected drug targets were examined by protein-protein 
interaction network analysis. The network analysis of 8 
enzymes and 2 vaccine candidates was determined using the 
STRING database. Interactions with a score of > 0.400 and 
interactions with < 50 interactors were regarded as potential 
drug targets. The analysis of STRING database showed that 
all the proposed drug targets showed interactions with the 
high confidence scores of 0.900 and with low confidence 
interactions less than 50 were incorporated in the 
interaction network. Each network gives a particular group 
of proteins. Hovering over each node will display its 
annotation and full details of the protein, here network 
nodes represent proteins. Each node in the network has its 
own importance. Clustering in STRING has two different 
parameters to cluster the proteins. KMEANS is the parameter 
which particularly specifies the number of clusters and MCL 
is the parameter that indirectly related to the precision of 
the clustering which is mentioned as ‘inflation’. The nodes 
can be deleted and change in the clustering was noted. Upon 
deletion of each node manually clustering MCL parameter or 
KMEANS parameter decrease in clustering coefficient was 
observed and considered as a functionally important protein 
in the metabolic network. Hence, all the drug targets were 
considered as potential targets for the pathogen causing 
tuberculosis. 
3.7. Vaccine candidate: 
As shown in table (1), The subcellular localization 
prediction determined that 8 enzymes were located in 
cytoplasmic side and 2 were in the surface exposed 
membrane (OMP) proteins. From VaxiJen server, the 
shortlisted OMPs with a score more than the threshold (0.4) 
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were predicted as good antigens and affirmed as subunit 
vaccines candidates. Among the common 10 proteins, two 
vaccine candidates such as Molybdenum transport system 
permease protein (ModB) and phosphate transport system 
permease protein (pstc1) was identified as common vaccine 
candidates for MTB strains causing tuberculosis. Hence, the 
identification of vaccine candidates would be a promising 
attempt towards designing T-cell epitope-driven common 
subunit vaccine for preventing M. tuberculosis infections. 
Similarly, two novel vaccine candidates are membrane 
components with highly antigenic to host, essential for 
pathogenesis, cell adhesion and to protect M. tuberculosis 
from osmotic gradients. The implementation of therapeutics 
such as inhibitor or vaccines against these proposed novel 
targets may become single or common therapeutic for 
several M. tuberculosis strains and could be effective due to 
targets involvement in vital pathways. Therefore, the results 
of the study will highlight the proposed novel targets as 
more potential therapeutic targets. 
4. CONCLUSION 
Globally, the emergence of multi-drug resistance among 
pathogenic M. tuberculosis is a growing concern in the 
medical field. The development of new antimicrobial agents 
against unexplored drug targets is of major concern to curb 
these problems. This paper describes and appraises the 
uncovering set of potential targets that are typically 
conserved in M. tuberculosis strains which present a new 
opportunity for the experimental biologists to test. We 
identified the pool of eight common potential drug targets 
and two surface exposed membrane proteins provides a 
basis for computer-aided drug and vaccine design strategies  
lending credence to our approach. Development of powerful 
drug molecules via in silico to in vivo pipelines against these 
putative targets may become potential therapeutics to 
combat present and upcoming drug-resistant M. tuberculosis 
strains as these are conserved targets critically essential for 
pathogens, non-homologous to human and gut-flora at 
sequence to structural level. Therefore, the proposed targets 
from the study would bring new possibility in obstructing 
the biological functions essential for the growth and survival 
of M. tuberculosis infections.  
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